We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-14.07%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.34B
AUM Growth
-$421M
Cap. Flow
+$11.7M
Cap. Flow %
0.5%
Top 10 Hldgs %
40.93%
Holding
221
New
9
Increased
52
Reduced
52
Closed
18

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$15.4M
2
MDT icon
Medtronic
MDT
+$13.3M
3
UNH icon
UnitedHealth
UNH
+$8.16M
4
ISRG icon
Intuitive Surgical
ISRG
+$7.42M
5
PFE icon
Pfizer
PFE
+$7.12M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$17M
2
AZN icon
AstraZeneca
AZN
+$11.3M
3
IDXX icon
Idexx Laboratories
IDXX
+$10.4M
4
VTRS icon
Viatris
VTRS
+$8.21M
5
OHI icon
Omega Healthcare
OHI
+$6.92M

Sector Composition

Rank Sector Weight
1 Healthcare 94.39%
2 Real Estate 2.48%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHC icon
101
Bausch Health
BHC
$2.25B
$3.55M 0.15%
192,000
– –
LOXO
102
DELISTED
Loxo Oncology, Inc
LOXO
$3.44M 0.15%
24,595
– –
RARE icon
103
Ultragenyx Pharmaceutical
RARE
$2.56B
$3.35M 0.14%
76,958
– –
WELL icon
104
Welltower
WELL
$170B
$3.16M 0.14%
45,560
– –
NKTR icon
105
Nektar Therapeutics
NKTR
$2.41B
$3.1M 0.13%
6,292
-7,873
-56% -$4.75M
WCG
106
DELISTED
Wellcare Health Plans, Inc.
WCG
$3.07M 0.13%
+13,000
New +$3.48M
ALBO
107
DELISTED
Albireo Pharma Inc
ALBO
$3.07M 0.13%
125,000
– –
PHG icon
108
Philips
PHG
$25.8B
$3M 0.13%
110,022
+67,379
+158% +$1.99M
VAR
109
DELISTED
Varian Medical Systems, Inc.
VAR
$2.97M 0.13%
26,227
– –
CHRS icon
110
Coherus Oncology
CHRS
$227M
$2.85M 0.12%
315,162
+165,342
+110% +$1.91M
INVA icon
111
Innoviva
INVA
$1.57B
$2.82M 0.12%
161,603
– –
SGMO
112
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$2.77M 0.12%
241,538
+69,649
+41% +$865K
NVRO
113
DELISTED
NEVRO CORP.
NVRO
$2.67M 0.11%
68,760
– –
ASND icon
114
Ascendis Pharma A/S
ASND
$16.5B
$2.66M 0.11%
42,399
-23,315
-35% -$1.46M
CRL icon
115
Charles River Laboratories
CRL
$11.3B
$2.57M 0.11%
22,670
– –
INOV
116
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
$2.5M 0.11%
176,163
– –
VRNA
117
DELISTED
Verona Pharma
VRNA
$2.48M 0.11%
275,000
– –
THC icon
118
Tenet Healthcare
THC
$21.8B
$2.42M 0.1%
141,136
-23,364
-14% -$565K
EPZM
119
DELISTED
Epizyme, Inc
EPZM
$2.38M 0.1%
385,872
-99,453
-20% -$760K
PTCT icon
120
PTC Therapeutics
PTCT
$6.26B
$2.36M 0.1%
68,652
+20,262
+42% +$729K
AGIO icon
121
Agios Pharmaceuticals
AGIO
$1.95B
$2.26M 0.1%
49,025
+15,155
+45% +$935K
PTLA
122
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$2.25M 0.1%
115,448
– –
MRNS
123
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$2.17M 0.09%
188,944
+104,887
+125% +$2.12M
FOMX
124
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$2.16M 0.09%
601,205
-126,000
-17% -$548K
AVDL
125
DELISTED
Avadel Pharmaceuticals
AVDL
$2.1M 0.09%
814,588
– –
3 4
5
6 7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2018 Portfolio in Review

As of Q4 2018, Tekla Capital Management held 221 positions worth $2.34B, down 15% from $2.76B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Tekla Capital Management's Q4 2018 filing shows 9 new, 52 increased, 52 reduced and 18 closed positions. Its largest new stake was Wellcare Health Plans, Inc.: 13,000 shares worth $3.07M. The largest sale was Aetna Inc, an estimated $17M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Real Estate and Financials.

  • Tekla Capital Management's largest Q4 2018 buy was Wellcare Health Plans, Inc.: 13,000 shares worth $3.07M.
  • Tekla Capital Management added most to Bristol-Myers Squibb in Q4 2018, an estimated $15.4M increase.
  • Tekla Capital Management's biggest Q4 2018 reduction was AstraZeneca, cutting an estimated $11.3M.
  • Tekla Capital Management fully exited Aetna Inc in Q4 2018, selling an estimated $17M.
  • Tekla Capital Management's ten largest holdings make up 41% of its $2.34B portfolio in Q4 2018.
  • Tekla Capital Management opened 9 new positions and closed 18 in Q4 2018.
  • Tekla Capital Management's portfolio value fell 15% quarter-over-quarter to $2.34B.

Based on Tekla Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.